As of June 21, 2025, Provectus Biopharmaceuticals Inc (PVCT) reports a Net Margin of -766.85%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Provectus Biopharmaceuticals Inc's Net Margin
Over recent years, Provectus Biopharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -766.85% |
| 2023-12-31 | -556.16% |
| 2022-12-31 | -358.59% |
This gradual decrease highlights how Provectus Biopharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Provectus Biopharmaceuticals Inc's Net Margin to Peers
To better understand Provectus Biopharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Provectus Biopharmaceuticals Inc (PVCT) | -766.85% |
| Biostem Technologies Inc (BSEM) | 10.56% |
| SugarBud Craft Growers Corp (SUGR.V) | 3.57% |
| Nextleaf Solutions Ltd (OILS.CN) | -11.51% |
| Avricore Health Inc (AVCR.V) | -13.98% |
| Canada House Cannabis Group Inc (CHV.CN) | -41.60% |
Compared to its competitors, Provectus Biopharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.